Dr. Zafar Sayed, MD

Dr. Sayed practices at Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut.

Dr. Sayed's NPI, 1407149404, was assigned on May 24, 2011. Dr. Sayed graduated from Indiana University School Of Medicine in 2011. Dr. Sayed holds Connecticut license 75333.

Dr. Sayed's primary practice is Yale New Haven Psychiatric Hospital (York St), at 20 York Street, New Haven, CT 06510. The practice phone is (203) 688-5900.

Dr. Sayed's primary practice is Yale New Haven Psychiatric Hospital (York St) in New Haven, Connecticut. Dr. Sayed is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Sayed to 4 more hospitals, 2 home health agencies, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sayed practices, 9 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Sayed's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dmand AI has Dr. Sayed's licenses on file in 2 states: Connecticut and Illinois.

CMS data shows 87 Medicare services from Dr. Sayed across 4 procedure codes in 2024, for 74 Medicare patients. Medicare paid $6,104 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 74 Medicare patients who saw Dr. Sayed in 2024. The largest group is 65 to 74, with 34 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sayed's median patient age at 69, with 40% women.

In 2024, Dr. Sayed wrote 46 Medicare Part D claims for 28 patients. 89% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $469 in total drug cost. In 2023, CMS named 39 claims across 2 drugs.

Dr. Sayed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sayed as offering telehealth.

Laminectomy or laminotomy (partial removal of spine bones): 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Sayed, published from 2019 to 2022. 2019 was the busiest year, with 3. The most frequent topics are Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms and Black or African American. Dr. Sayed has published most often in Cancer Lett. Dr. Sayed's most frequent co-authors are Surinder K. Batra, MD, Dwight T. Jones, MD and Christopher Andrew Barker, MD.

CMS Open Payments shows 21 general payments to Dr. Sayed from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 56% of the total. Stryker Corporation paid the most, $874.

Dr. Sayed graduated from Indiana University School Of Medicine in 2011.